These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 14569053

  • 1. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.
    Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A.
    J Pharmacol Exp Ther; 2004 Jan; 308(1):236-40. PubMed ID: 14569053
    [Abstract] [Full Text] [Related]

  • 2. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.
    Monnet X, Ghaleh B, Colin P, de Curzon OP, Giudicelli JF, Berdeaux A.
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904
    [Abstract] [Full Text] [Related]

  • 3. Heart rate reduction during exercise-induced myocardial ischaemia and stunning.
    Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A.
    Eur Heart J; 2004 Apr; 25(7):579-86. PubMed ID: 15120055
    [Abstract] [Full Text] [Related]

  • 4. Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening.
    Lucats L, Ghaleh B, Colin P, Monnet X, Bizé A, Berdeaux A.
    Br J Pharmacol; 2007 Feb; 150(3):335-41. PubMed ID: 17179940
    [Abstract] [Full Text] [Related]

  • 5. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C.
    Circulation; 2004 Apr 06; 109(13):1674-9. PubMed ID: 14981003
    [Abstract] [Full Text] [Related]

  • 6. Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning.
    Lucats L, Ghaleh B, Monnet X, Colin P, Bizé A, Berdeaux A.
    Eur Heart J; 2007 Apr 06; 28(7):872-9. PubMed ID: 17376788
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic heart rate reduction: effect of a novel, specific bradycardic agent on the heart.
    Granetzny A, Schwanke U, Schmitz C, Arnold G, Schäfer D, Schulte HD, Gams E, Schipke JD.
    Thorac Cardiovasc Surg; 1998 Apr 06; 46(2):63-9. PubMed ID: 9618805
    [Abstract] [Full Text] [Related]

  • 8. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC, Reil GH, Böhm M.
    Trends Cardiovasc Med; 2009 Jul 06; 19(5):152-7. PubMed ID: 20005474
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of ivabradine on heart rate and left ventricular function in healthy cats and cats with hypertrophic cardiomyopathy.
    Riesen SC, Schober KE, Smith DN, Otoni CC, Li X, Bonagura JD.
    Am J Vet Res; 2012 Feb 06; 73(2):202-12. PubMed ID: 22280379
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 15. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R, Ceconi C.
    Expert Rev Cardiovasc Ther; 2011 Aug 27; 9(8):959-73. PubMed ID: 21878041
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients.
    Doesch AO, Ammon K, Konstandin M, Celik S, Kristen A, Frankenstein L, Buss S, Hardt S, Sack FU, Katus HA, Dengler TJ.
    Transplantation; 2009 Sep 27; 88(6):835-41. PubMed ID: 19920784
    [Abstract] [Full Text] [Related]

  • 19. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction.
    Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R.
    Eur Heart J; 2008 Sep 27; 29(18):2265-75. PubMed ID: 18621770
    [Abstract] [Full Text] [Related]

  • 20. Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction.
    Bakkehaug JP, Naesheim T, Torgersen Engstad E, Kildal AB, Myrmel T, How OJ.
    Acta Physiol (Oxf); 2016 Oct 27; 218(2):78-88. PubMed ID: 27145482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.